VIVUS Announces $11.55 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
01 avr. 2020 09h02 HE
|
VIVUS, Inc.
CAMPBELL, Calif., April 01, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, today announced that it has entered into definitive agreements with...
VIVUS Reports Fourth Quarter 2018 Financial Results
26 févr. 2019 16h05 HE
|
VIVUS, Inc.
Company to host conference call today at 4:30pm ET CAMPBELL, Calif., Feb. 26, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (NASDAQ: VVUS) (the "Company"), a specialty pharmaceutical company committed to...
VIVUS to Host Fourth Quarter and Full Year Business Update and Financial Results Conference Call on Tuesday, February 26, 2019
13 févr. 2019 07h30 HE
|
VIVUS, Inc.
CAMPBELL, Calif., Feb. 13, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) today announced that it will report financial results and provide a business update for the fourth quarter and full...
VIVUS Announces Date of 2019 Annual Meeting
04 févr. 2019 16h00 HE
|
VIVUS, Inc.
CAMPBELL, Calif., Feb. 04, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, today announced that the Company will hold its 2019 Annual Meeting of...
Data Supporting the Cardiovascular Safety of VIVUS’ Qsymia® Published in The Journal of Clinical Endocrinology & Metabolism
14 janv. 2019 07h30 HE
|
VIVUS, Inc.
CAMPBELL, Calif., Jan. 14, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, today announced that results from a new study evaluating the...
VIVUS to Present at Biotech Showcase on January 9, 2019
27 déc. 2018 07h30 HE
|
VIVUS, Inc.
CAMPBELL, Calif., Dec. 27, 2018 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a specialty pharmaceutical company committed to the development and commercialization of innovative...
VIVUS Reports Third Quarter 2018 Financial Results
01 nov. 2018 16h10 HE
|
VIVUS, Inc.
Company to host conference call today at 4:30pm ET CAMPBELL, Calif., Nov. 01, 2018 (GLOBE NEWSWIRE) -- VIVUS, Inc. (NASDAQ: VVUS) (the "Company"), a specialty pharmaceutical company committed to...
VIVUS Adds Two New Members to the Board of Directors
29 oct. 2018 07h30 HE
|
VIVUS, Inc.
Karen Ferrell and Edward A. Kangas Expand VIVUS’ Board to Nine Members CAMPBELL, Calif., Oct. 29, 2018 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company,...
VIVUS to Host Third Quarter Business Update and Financial Results Conference Call on Thursday, November 1, 2018
26 oct. 2018 07h30 HE
|
VIVUS, Inc.
CAMPBELL, Calif., Oct. 26, 2018 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) today announced that it will report financial results and provide a business update for the third quarter of 2018 after...
VIVUS to Present at the BIO Investor Forum on October 17, 2018
10 oct. 2018 07h30 HE
|
VIVUS, Inc.
CAMPBELL, Calif., Oct. 10, 2018 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a specialty pharmaceutical company committed to the development and commercialization of innovative...